Pediatric Neuro-Oncology Unit, Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona, Spain.
Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
J Neurooncol. 2018 Oct;140(1):1-4. doi: 10.1007/s11060-018-2938-x. Epub 2018 Jul 11.
Gliomatosis cerebri (GC) is an aggressive glioma characterized by an invasive growth pattern and a dismal prognosis. The low incidence and non-specific symptoms at presentation pose unique challenges for early diagnosis and disease-specific research. There is no standard of care for the treatment of patients with a GC phenotype. Understanding the biology of this entity is a critical step in determining effective treatments. Toward this end, the Second International GC Group convened at National Institutes of Health, Bethesda on June 22nd-23rd 2017. This paper summarizes the main conclusions and recommendations for research priorities to fight this fatal condition.
脑胶质瘤病（GC）是一种侵袭性胶质瘤，其特征为浸润性生长模式和不良预后。该病发病率低，起病时症状无特异性，这给早期诊断和疾病特异性研究带来了独特的挑战。目前，针对 GC 表型患者，尚无标准的治疗方法。了解该实体的生物学特性是确定有效治疗方法的关键步骤。为此，第二届国际 GC 小组于 2017 年 6 月 22 日至 23 日在贝塞斯达的美国国立卫生研究院召开了会议。本文总结了主要结论和建议，以确定研究重点，攻克这一致命疾病。
